Truist Financial Corp Acquires 1,813 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Truist Financial Corp increased its position in Exact Sciences Co. (NASDAQ:EXAS) by 6.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,932 shares of the medical research company’s stock after buying an additional 1,813 shares during the period. Truist Financial Corp’s holdings in Exact Sciences were worth $2,762,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of EXAS. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in shares of Exact Sciences by 19.9% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 31,236 shares of the medical research company’s stock worth $3,883,000 after buying an additional 5,193 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Exact Sciences by 34.1% in the second quarter. Rockefeller Capital Management L.P. now owns 22,296 shares of the medical research company’s stock worth $2,771,000 after buying an additional 5,671 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Exact Sciences by 1.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 196,092 shares of the medical research company’s stock worth $24,376,000 after buying an additional 3,053 shares in the last quarter. Atria Investments LLC lifted its position in shares of Exact Sciences by 5.6% in the second quarter. Atria Investments LLC now owns 8,459 shares of the medical research company’s stock worth $1,052,000 after buying an additional 449 shares in the last quarter. Finally, Toronto Dominion Bank lifted its position in shares of Exact Sciences by 6.2% in the second quarter. Toronto Dominion Bank now owns 22,829 shares of the medical research company’s stock worth $2,838,000 after buying an additional 1,337 shares in the last quarter. Institutional investors own 90.22% of the company’s stock.

In other news, CEO Kevin T. Conroy sold 16,922 shares of the business’s stock in a transaction on Monday, November 1st. The shares were sold at an average price of $93.88, for a total transaction of $1,588,637.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.40% of the stock is currently owned by insiders.

A number of equities research analysts have issued reports on EXAS shares. BTIG Research decreased their price objective on Exact Sciences from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, November 3rd. Wells Fargo & Company decreased their price objective on Exact Sciences from $120.00 to $95.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 3rd. Raymond James downgraded Exact Sciences from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $160.00 to $130.00 in a research report on Wednesday, November 3rd. Craig Hallum decreased their price objective on Exact Sciences from $144.00 to $133.00 and set a “buy” rating on the stock in a research report on Wednesday, November 3rd. Finally, SVB Leerink decreased their price objective on Exact Sciences from $160.00 to $140.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $136.64.

Shares of EXAS opened at $78.43 on Friday. The firm has a market capitalization of $13.51 billion, a P/E ratio of -15.78 and a beta of 1.22. Exact Sciences Co. has a 12-month low of $69.75 and a 12-month high of $159.54. The company has a current ratio of 2.27, a quick ratio of 2.14 and a debt-to-equity ratio of 0.55. The firm has a fifty day moving average price of $81.97 and a 200-day moving average price of $96.01.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, November 1st. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.08). The company had revenue of $456.38 million for the quarter, compared to analysts’ expectations of $429.04 million. Exact Sciences had a negative net margin of 46.14% and a negative return on equity of 11.53%. During the same period in the prior year, the firm posted ($0.36) earnings per share. Analysts predict that Exact Sciences Co. will post -3.13 earnings per share for the current year.

About Exact Sciences

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Recommended Story: Example of operating income, EBIT and EBITDA

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.